Advertisement

Index by author

May 01, 2006; Volume 34,Issue 5

A

  1. Abadie, Catherine

    1. GENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATING
      Lysiane Richert, Michael J. Liguori, Catherine Abadie, Bruno Heyd, Georges Mantion, Nermin Halkic and Jeffrey F. Waring
      Drug Metabolism and Disposition May 2006, 34 (5) 870-879; DOI: https://doi.org/10.1124/dmd.105.007708

  2. Abe, Takaaki

    1. OATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKER
      Rie Nakagomi-Hagihara, Daisuke Nakai, Kenji Kawai, Yasushi Yoshigae, Taro Tokui, Takaaki Abe and Toshihiko Ikeda
      Drug Metabolism and Disposition May 2006, 34 (5) 862-869; DOI: https://doi.org/10.1124/dmd.105.008888

  3. Aizawa, Yoshio

    1. DETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTS
      Rika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi Yamazoe
      Drug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623

  4. Akiyama, Yuji

    1. DETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTS
      Rika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi Yamazoe
      Drug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623

  5. Atack, John R.

    1. RAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708
      John R. Atack, Andy Pike, Ashley Clarke, Susan M. Cook, Bindi Sohal, Ruth M. McKernan and Gerard R. Dawson
      Drug Metabolism and Disposition May 2006, 34 (5) 887-893; DOI: https://doi.org/10.1124/dmd.105.006973

B

  1. Balakrishnan, Anand

    1. IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES
      Jarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. Polli
      Drug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615

  2. Baldeck, Jean-Pierre

    1. PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO
      Markus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. Grassberger
      Drug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732

  3. Becker, Stacey

    1. EVALUATION OF THE UTILITY OF BRAIN SLICE METHODS TO STUDY BRAIN PENETRATION
      Stacey Becker and Xingrong Liu
      Drug Metabolism and Disposition May 2006, 34 (5) 855-861; DOI: https://doi.org/10.1124/dmd.105.007914

  4. Berthier, Stephane

    1. PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO
      Markus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. Grassberger
      Drug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732

  5. Bertino, Joseph S.

    1. DURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAM
      Joseph D. Ma, Anne N. Nafziger, Gerry Rhodes, Siyu Liu and Joseph S. Bertino
      Drug Metabolism and Disposition May 2006, 34 (5) 783-785; DOI: https://doi.org/10.1124/dmd.105.007831

  6. Blanchard, Andrew P.

    1. HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81
      J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James Wong
      Drug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569

C

  1. Caldwell, G. W.

    1. N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES
      Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. Johnson
      Drug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274

  2. Chandler, Catherine

    1. HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81
      J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James Wong
      Drug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569

  3. Charman, William N.

    1. AN EXAMINATION OF THE INTERPLAY BETWEEN ENTEROCYTE-BASED METABOLISM AND LYMPHATIC DRUG TRANSPORT IN THE RAT
      Natalie L. Trevaskis, Christopher J.H. Porter and William N. Charman
      Drug Metabolism and Disposition May 2006, 34 (5) 729-733; DOI: https://doi.org/10.1124/dmd.105.008102

  4. Chen, Chieh-Fu

    1. OXIDATIVE METABOLISM OF THE ALKALOID RUTAECARPINE BY HUMAN CYTOCHROME P450
      Yune-Fang Ueng, Ming-Jaw Don, Woan-Ching Jan, Shu-Yun Wang, Li-Kang Ho and Chieh-Fu Chen
      Drug Metabolism and Disposition May 2006, 34 (5) 821-827; DOI: https://doi.org/10.1124/dmd.105.007849

  5. Cheng, Peter T.

    1. BIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITES
      Wenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith Humphreys
      Drug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856

  6. Chiang, John Y. L.

    1. RIFAMPICIN INDUCTION OF CYP3A4 REQUIRES PREGNANE X RECEPTOR CROSS TALK WITH HEPATOCYTE NUCLEAR FACTOR 4α AND COACTIVATORS, AND SUPPRESSION OF SMALL HETERODIMER PARTNER GENE EXPRESSION
      Tiangang Li and John Y. L. Chiang
      Drug Metabolism and Disposition May 2006, 34 (5) 756-764; DOI: https://doi.org/10.1124/dmd.105.007575

  7. Clark, Robert J.

    1. HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81
      J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James Wong
      Drug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569

  8. Clarke, Ashley

    1. RAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708
      John R. Atack, Andy Pike, Ashley Clarke, Susan M. Cook, Bindi Sohal, Ruth M. McKernan and Gerard R. Dawson
      Drug Metabolism and Disposition May 2006, 34 (5) 887-893; DOI: https://doi.org/10.1124/dmd.105.006973

  9. Cook, Susan M.

    1. RAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708
      John R. Atack, Andy Pike, Ashley Clarke, Susan M. Cook, Bindi Sohal, Ruth M. McKernan and Gerard R. Dawson
      Drug Metabolism and Disposition May 2006, 34 (5) 887-893; DOI: https://doi.org/10.1124/dmd.105.006973

  10. Crespi, Charles L.

    1. HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81
      J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James Wong
      Drug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569

D

  1. Dai, Yang

    1. EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO
      Yang Dai, Mary F. Hebert, Nina Isoherranen, Connie L. Davis, Christopher Marsh, Danny D. Shen and Kenneth E. Thummel
      Drug Metabolism and Disposition May 2006, 34 (5) 836-847; DOI: https://doi.org/10.1124/dmd.105.008680

  2. Davis, Connie L.

    1. EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO
      Yang Dai, Mary F. Hebert, Nina Isoherranen, Connie L. Davis, Christopher Marsh, Danny D. Shen and Kenneth E. Thummel
      Drug Metabolism and Disposition May 2006, 34 (5) 836-847; DOI: https://doi.org/10.1124/dmd.105.008680

  3. Dawson, Gerard R.

    1. RAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708
      John R. Atack, Andy Pike, Ashley Clarke, Susan M. Cook, Bindi Sohal, Ruth M. McKernan and Gerard R. Dawson
      Drug Metabolism and Disposition May 2006, 34 (5) 887-893; DOI: https://doi.org/10.1124/dmd.105.006973

  4. Dehal, Shangara S.

    1. HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81
      J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James Wong
      Drug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569

  5. Don, Ming-Jaw

    1. OXIDATIVE METABOLISM OF THE ALKALOID RUTAECARPINE BY HUMAN CYTOCHROME P450
      Yune-Fang Ueng, Ming-Jaw Don, Woan-Ching Jan, Shu-Yun Wang, Li-Kang Ho and Chieh-Fu Chen
      Drug Metabolism and Disposition May 2006, 34 (5) 821-827; DOI: https://doi.org/10.1124/dmd.105.007849

  6. Dorani, Hassan

    1. INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION
      Ulf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie Schützer
      Drug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607

E

  1. Eriksson, Ulf G.

    1. INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION
      Ulf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie Schützer
      Drug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607

  2. Everett, Donald W.

    1. BIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITES
      Wenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith Humphreys
      Drug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856

F

  1. Fritsch, Holger

    1. INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION
      Ulf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie Schützer
      Drug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607

  2. Fukuda, Hajime

    1. EFFECT OF P-GLYCOPROTEIN ON INTESTINAL ABSORPTION AND BRAIN PENETRATION OF ANTIALLERGIC AGENT BEPOTASTINE BESILATE
      Rikiya Ohashi, Yukari Kamikozawa, Mika Sugiura, Hajime Fukuda, Hikaru Yabuuchi and Ikumi Tamai
      Drug Metabolism and Disposition May 2006, 34 (5) 793-799; DOI: https://doi.org/10.1124/dmd.105.007559

  3. Fuse, Eiichi

    1. INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID
      Harunobu Tahara, Hiroyuki Kusuhara, Kazuya Maeda, Hermann Koepsell, Eiichi Fuse and Yuichi Sugiyama
      Drug Metabolism and Disposition May 2006, 34 (5) 743-747; DOI: https://doi.org/10.1124/dmd.105.008375

G

  1. Galemmo, R. A.

    1. N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES
      Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. Johnson
      Drug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274

  2. Gauthier, D.

    1. N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES
      Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. Johnson
      Drug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274

  3. Gilmore, W. James

    1. THE ROLE OF CYP2A AND CYP2E1 IN THE METABOLISM OF 3-METHYLINDOLE IN PRIMARY CULTURED PORCINE HEPATOCYTES
      Michael A. Terner, W. James Gilmore, Yanping Lou and E. James Squires
      Drug Metabolism and Disposition May 2006, 34 (5) 848-854; DOI: https://doi.org/10.1124/dmd.105.008128

  4. Glaenzel, Ulrike

    1. PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO
      Markus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. Grassberger
      Drug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732

  5. Goda, Rika

    1. DETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTS
      Rika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi Yamazoe
      Drug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623

  6. Grassberger, Maximilian A.

    1. PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO
      Markus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. Grassberger
      Drug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732

  7. Grimm, Scott

    1. ATP-DEPENDENT TRANSPORT OF ROSUVASTATIN IN MEMBRANE VESICLES EXPRESSING BREAST CANCER RESISTANCE PROTEIN
      Liyue Huang, Yi Wang and Scott Grimm
      Drug Metabolism and Disposition May 2006, 34 (5) 738-742; DOI: https://doi.org/10.1124/dmd.105.007534

H

  1. Haining, Robert L.

    1. THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
      Mary F. Paine, Heather L. Hart, Shana S. Ludington, Robert L. Haining, Allan E. Rettie and Darryl C. Zeldin
      Drug Metabolism and Disposition May 2006, 34 (5) 880-886; DOI: https://doi.org/10.1124/dmd.105.008672

  2. Halkic, Nermin

    1. GENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATING
      Lysiane Richert, Michael J. Liguori, Catherine Abadie, Bruno Heyd, Georges Mantion, Nermin Halkic and Jeffrey F. Waring
      Drug Metabolism and Disposition May 2006, 34 (5) 870-879; DOI: https://doi.org/10.1124/dmd.105.007708

  3. Hart, Heather L.

    1. THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
      Mary F. Paine, Heather L. Hart, Shana S. Ludington, Robert L. Haining, Allan E. Rettie and Darryl C. Zeldin
      Drug Metabolism and Disposition May 2006, 34 (5) 880-886; DOI: https://doi.org/10.1124/dmd.105.008672

  4. Hartmann, Stefan

    1. PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO
      Markus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. Grassberger
      Drug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732

  5. Hebert, Mary F.

    1. EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO
      Yang Dai, Mary F. Hebert, Nina Isoherranen, Connie L. Davis, Christopher Marsh, Danny D. Shen and Kenneth E. Thummel
      Drug Metabolism and Disposition May 2006, 34 (5) 836-847; DOI: https://doi.org/10.1124/dmd.105.008680

  6. Heyd, Bruno

    1. GENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATING
      Lysiane Richert, Michael J. Liguori, Catherine Abadie, Bruno Heyd, Georges Mantion, Nermin Halkic and Jeffrey F. Waring
      Drug Metabolism and Disposition May 2006, 34 (5) 870-879; DOI: https://doi.org/10.1124/dmd.105.007708

  7. Ho, C. Y.

    1. N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES
      Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. Johnson
      Drug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274

  8. Ho, Li-Kang

    1. OXIDATIVE METABOLISM OF THE ALKALOID RUTAECARPINE BY HUMAN CYTOCHROME P450
      Yune-Fang Ueng, Ming-Jaw Don, Woan-Ching Jan, Shu-Yun Wang, Li-Kang Ho and Chieh-Fu Chen
      Drug Metabolism and Disposition May 2006, 34 (5) 821-827; DOI: https://doi.org/10.1124/dmd.105.007849

  9. Ho, Thuy

    1. HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81
      J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James Wong
      Drug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569

  10. Hoffmann, Kurt-Jürgen

    1. INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION
      Ulf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie Schützer
      Drug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607

  11. Huang, Liyue

    1. ATP-DEPENDENT TRANSPORT OF ROSUVASTATIN IN MEMBRANE VESICLES EXPRESSING BREAST CANCER RESISTANCE PROTEIN
      Liyue Huang, Yi Wang and Scott Grimm
      Drug Metabolism and Disposition May 2006, 34 (5) 738-742; DOI: https://doi.org/10.1124/dmd.105.007534

  12. Humphreys, Joan E.

    1. IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES
      Jarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. Polli
      Drug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615

  13. Humphreys, W. Griffith

    1. BIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITES
      Wenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith Humphreys
      Drug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856

I

  1. Ikeda, Toshihiko

    1. OATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKER
      Rie Nakagomi-Hagihara, Daisuke Nakai, Kenji Kawai, Yasushi Yoshigae, Taro Tokui, Takaaki Abe and Toshihiko Ikeda
      Drug Metabolism and Disposition May 2006, 34 (5) 862-869; DOI: https://doi.org/10.1124/dmd.105.008888

  2. Ikemoto, Isao

    1. DETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTS
      Rika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi Yamazoe
      Drug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623

  3. Isoherranen, Nina

    1. EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO
      Yang Dai, Mary F. Hebert, Nina Isoherranen, Connie L. Davis, Christopher Marsh, Danny D. Shen and Kenneth E. Thummel
      Drug Metabolism and Disposition May 2006, 34 (5) 836-847; DOI: https://doi.org/10.1124/dmd.105.008680

J

  1. Jan, Woan-Ching

    1. OXIDATIVE METABOLISM OF THE ALKALOID RUTAECARPINE BY HUMAN CYTOCHROME P450
      Yune-Fang Ueng, Ming-Jaw Don, Woan-Ching Jan, Shu-Yun Wang, Li-Kang Ho and Chieh-Fu Chen
      Drug Metabolism and Disposition May 2006, 34 (5) 821-827; DOI: https://doi.org/10.1124/dmd.105.007849

  2. Johnson, D. L.

    1. N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES
      Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. Johnson
      Drug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274

  3. Johnson, Jennifer

    1. HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81
      J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James Wong
      Drug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569

  4. Jones, W. J.

    1. N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES
      Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. Johnson
      Drug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274

K

  1. Kamikozawa, Yukari

    1. EFFECT OF P-GLYCOPROTEIN ON INTESTINAL ABSORPTION AND BRAIN PENETRATION OF ANTIALLERGIC AGENT BEPOTASTINE BESILATE
      Rikiya Ohashi, Yukari Kamikozawa, Mika Sugiura, Hajime Fukuda, Hikaru Yabuuchi and Ikumi Tamai
      Drug Metabolism and Disposition May 2006, 34 (5) 793-799; DOI: https://doi.org/10.1124/dmd.105.007559

  2. Kamimura, Hidetaka

    1. THE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITOR
      Daisuke Tenmizu, Kiyoshi Noguchi, Hidetaka Kamimura, Hisakazu Ohtani and Yasufumi Sawada
      Drug Metabolism and Disposition May 2006, 34 (5) 800-806; DOI: https://doi.org/10.1124/dmd.105.008722

  3. Karlsson, Johan

    1. INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION
      Ulf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie Schützer
      Drug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607

  4. Kawai, Kenji

    1. OATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKER
      Rie Nakagomi-Hagihara, Daisuke Nakai, Kenji Kawai, Yasushi Yoshigae, Taro Tokui, Takaaki Abe and Toshihiko Ikeda
      Drug Metabolism and Disposition May 2006, 34 (5) 862-869; DOI: https://doi.org/10.1124/dmd.105.008888

  5. Keogh, John P.

    1. IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES
      Jarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. Polli
      Drug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615

  6. Koepsell, Hermann

    1. INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID
      Harunobu Tahara, Hiroyuki Kusuhara, Kazuya Maeda, Hermann Koepsell, Eiichi Fuse and Yuichi Sugiyama
      Drug Metabolism and Disposition May 2006, 34 (5) 743-747; DOI: https://doi.org/10.1124/dmd.105.008375

  7. Kunta, Jeevan R.

    1. IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES
      Jarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. Polli
      Drug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615

  8. Kusuhara, Hiroyuki

    1. INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID
      Harunobu Tahara, Hiroyuki Kusuhara, Kazuya Maeda, Hermann Koepsell, Eiichi Fuse and Yuichi Sugiyama
      Drug Metabolism and Disposition May 2006, 34 (5) 743-747; DOI: https://doi.org/10.1124/dmd.105.008375

L

  1. Leo, G. C.

    1. N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES
      Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. Johnson
      Drug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274

  2. Li, Tiangang

    1. RIFAMPICIN INDUCTION OF CYP3A4 REQUIRES PREGNANE X RECEPTOR CROSS TALK WITH HEPATOCYTE NUCLEAR FACTOR 4α AND COACTIVATORS, AND SUPPRESSION OF SMALL HETERODIMER PARTNER GENE EXPRESSION
      Tiangang Li and John Y. L. Chiang
      Drug Metabolism and Disposition May 2006, 34 (5) 756-764; DOI: https://doi.org/10.1124/dmd.105.007575

  3. Li, Wenying

    1. BIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITES
      Wenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith Humphreys
      Drug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856

  4. Liguori, Michael J.

    1. GENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATING
      Lysiane Richert, Michael J. Liguori, Catherine Abadie, Bruno Heyd, Georges Mantion, Nermin Halkic and Jeffrey F. Waring
      Drug Metabolism and Disposition May 2006, 34 (5) 870-879; DOI: https://doi.org/10.1124/dmd.105.007708

  5. Liu, Siyu

    1. DURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAM
      Joseph D. Ma, Anne N. Nafziger, Gerry Rhodes, Siyu Liu and Joseph S. Bertino
      Drug Metabolism and Disposition May 2006, 34 (5) 783-785; DOI: https://doi.org/10.1124/dmd.105.007831

  6. Liu, Xingrong

    1. EVALUATION OF THE UTILITY OF BRAIN SLICE METHODS TO STUDY BRAIN PENETRATION
      Stacey Becker and Xingrong Liu
      Drug Metabolism and Disposition May 2006, 34 (5) 855-861; DOI: https://doi.org/10.1124/dmd.105.007914

  7. Lou, Yanping

    1. THE ROLE OF CYP2A AND CYP2E1 IN THE METABOLISM OF 3-METHYLINDOLE IN PRIMARY CULTURED PORCINE HEPATOCYTES
      Michael A. Terner, W. James Gilmore, Yanping Lou and E. James Squires
      Drug Metabolism and Disposition May 2006, 34 (5) 848-854; DOI: https://doi.org/10.1124/dmd.105.008128

  8. Ludington, Shana S.

    1. THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
      Mary F. Paine, Heather L. Hart, Shana S. Ludington, Robert L. Haining, Allan E. Rettie and Darryl C. Zeldin
      Drug Metabolism and Disposition May 2006, 34 (5) 880-886; DOI: https://doi.org/10.1124/dmd.105.008672

M

  1. Ma, Joseph D.

    1. DURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAM
      Joseph D. Ma, Anne N. Nafziger, Gerry Rhodes, Siyu Liu and Joseph S. Bertino
      Drug Metabolism and Disposition May 2006, 34 (5) 783-785; DOI: https://doi.org/10.1124/dmd.105.007831

  2. Maeda, Kazuya

    1. INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID
      Harunobu Tahara, Hiroyuki Kusuhara, Kazuya Maeda, Hermann Koepsell, Eiichi Fuse and Yuichi Sugiyama
      Drug Metabolism and Disposition May 2006, 34 (5) 743-747; DOI: https://doi.org/10.1124/dmd.105.008375

  3. Mantion, Georges

    1. GENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATING
      Lysiane Richert, Michael J. Liguori, Catherine Abadie, Bruno Heyd, Georges Mantion, Nermin Halkic and Jeffrey F. Waring
      Drug Metabolism and Disposition May 2006, 34 (5) 870-879; DOI: https://doi.org/10.1124/dmd.105.007708

  4. Marsh, Christopher

    1. EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO
      Yang Dai, Mary F. Hebert, Nina Isoherranen, Connie L. Davis, Christopher Marsh, Danny D. Shen and Kenneth E. Thummel
      Drug Metabolism and Disposition May 2006, 34 (5) 836-847; DOI: https://doi.org/10.1124/dmd.105.008680

  5. Masucci, J. A.

    1. N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES
      Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. Johnson
      Drug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274

  6. McKernan, Ruth M.

    1. RAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708
      John R. Atack, Andy Pike, Ashley Clarke, Susan M. Cook, Bindi Sohal, Ruth M. McKernan and Gerard R. Dawson
      Drug Metabolism and Disposition May 2006, 34 (5) 887-893; DOI: https://doi.org/10.1124/dmd.105.006973

  7. Mei, J.

    1. N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES
      Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. Johnson
      Drug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274

  8. Moenius, Thomas

    1. PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO
      Markus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. Grassberger
      Drug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732

N

  1. Nafziger, Anne N.

    1. DURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAM
      Joseph D. Ma, Anne N. Nafziger, Gerry Rhodes, Siyu Liu and Joseph S. Bertino
      Drug Metabolism and Disposition May 2006, 34 (5) 783-785; DOI: https://doi.org/10.1124/dmd.105.007831

  2. Nagai, Daichi

    1. DETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTS
      Rika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi Yamazoe
      Drug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623

  3. Nagata, Kiyoshi

    1. DETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTS
      Rika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi Yamazoe
      Drug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623

  4. Nakagomi-Hagihara, Rie

    1. OATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKER
      Rie Nakagomi-Hagihara, Daisuke Nakai, Kenji Kawai, Yasushi Yoshigae, Taro Tokui, Takaaki Abe and Toshihiko Ikeda
      Drug Metabolism and Disposition May 2006, 34 (5) 862-869; DOI: https://doi.org/10.1124/dmd.105.008888

  5. Nakai, Daisuke

    1. OATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKER
      Rie Nakagomi-Hagihara, Daisuke Nakai, Kenji Kawai, Yasushi Yoshigae, Taro Tokui, Takaaki Abe and Toshihiko Ikeda
      Drug Metabolism and Disposition May 2006, 34 (5) 862-869; DOI: https://doi.org/10.1124/dmd.105.008888

  6. Nishikawa, Kiyohiro

    1. DETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTS
      Rika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi Yamazoe
      Drug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623

  7. Noguchi, Kiyoshi

    1. THE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITOR
      Daisuke Tenmizu, Kiyoshi Noguchi, Hidetaka Kamimura, Hisakazu Ohtani and Yasufumi Sawada
      Drug Metabolism and Disposition May 2006, 34 (5) 800-806; DOI: https://doi.org/10.1124/dmd.105.008722

O

  1. Ohashi, Rikiya

    1. EFFECT OF P-GLYCOPROTEIN ON INTESTINAL ABSORPTION AND BRAIN PENETRATION OF ANTIALLERGIC AGENT BEPOTASTINE BESILATE
      Rikiya Ohashi, Yukari Kamikozawa, Mika Sugiura, Hajime Fukuda, Hikaru Yabuuchi and Ikumi Tamai
      Drug Metabolism and Disposition May 2006, 34 (5) 793-799; DOI: https://doi.org/10.1124/dmd.105.007559

  2. Ohtani, Hisakazu

    1. THE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITOR
      Daisuke Tenmizu, Kiyoshi Noguchi, Hidetaka Kamimura, Hisakazu Ohtani and Yasufumi Sawada
      Drug Metabolism and Disposition May 2006, 34 (5) 800-806; DOI: https://doi.org/10.1124/dmd.105.008722

  3. Olsson, Lis

    1. INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION
      Ulf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie Schützer
      Drug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607

P

  1. Paine, Mary F.

    1. THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
      Mary F. Paine, Heather L. Hart, Shana S. Ludington, Robert L. Haining, Allan E. Rettie and Darryl C. Zeldin
      Drug Metabolism and Disposition May 2006, 34 (5) 880-886; DOI: https://doi.org/10.1124/dmd.105.008672

  2. Pike, Andy

    1. RAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708
      John R. Atack, Andy Pike, Ashley Clarke, Susan M. Cook, Bindi Sohal, Ruth M. McKernan and Gerard R. Dawson
      Drug Metabolism and Disposition May 2006, 34 (5) 887-893; DOI: https://doi.org/10.1124/dmd.105.006973

  3. Polli, Joseph W.

    1. IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES
      Jarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. Polli
      Drug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615

  4. Porter, Christopher J.H.

    1. AN EXAMINATION OF THE INTERPLAY BETWEEN ENTEROCYTE-BASED METABOLISM AND LYMPHATIC DRUG TRANSPORT IN THE RAT
      Natalie L. Trevaskis, Christopher J.H. Porter and William N. Charman
      Drug Metabolism and Disposition May 2006, 34 (5) 729-733; DOI: https://doi.org/10.1124/dmd.105.008102

R

  1. Rautio, Jarkko

    1. IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES
      Jarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. Polli
      Drug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615

  2. Rettie, Allan E.

    1. THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
      Mary F. Paine, Heather L. Hart, Shana S. Ludington, Robert L. Haining, Allan E. Rettie and Darryl C. Zeldin
      Drug Metabolism and Disposition May 2006, 34 (5) 880-886; DOI: https://doi.org/10.1124/dmd.105.008672

  3. Rhodes, Gerry

    1. DURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAM
      Joseph D. Ma, Anne N. Nafziger, Gerry Rhodes, Siyu Liu and Joseph S. Bertino
      Drug Metabolism and Disposition May 2006, 34 (5) 783-785; DOI: https://doi.org/10.1124/dmd.105.007831

  4. Richert, Lysiane

    1. GENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATING
      Lysiane Richert, Michael J. Liguori, Catherine Abadie, Bruno Heyd, Georges Mantion, Nermin Halkic and Jeffrey F. Waring
      Drug Metabolism and Disposition May 2006, 34 (5) 870-879; DOI: https://doi.org/10.1124/dmd.105.007708

S

  1. Sarich, Troy C.

    1. INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION
      Ulf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie Schützer
      Drug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607

  2. Sawada, Yasufumi

    1. THE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITOR
      Daisuke Tenmizu, Kiyoshi Noguchi, Hidetaka Kamimura, Hisakazu Ohtani and Yasufumi Sawada
      Drug Metabolism and Disposition May 2006, 34 (5) 800-806; DOI: https://doi.org/10.1124/dmd.105.008722

  3. Schützer, Kajs-Marie

    1. INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION
      Ulf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie Schützer
      Drug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607

  4. Schweitzer, Alain

    1. PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO
      Markus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. Grassberger
      Drug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732

  5. Serabjit-Singh, Cosette J.

    1. IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES
      Jarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. Polli
      Drug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615

  6. Shen, Danny D.

    1. EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO
      Yang Dai, Mary F. Hebert, Nina Isoherranen, Connie L. Davis, Christopher Marsh, Danny D. Shen and Kenneth E. Thummel
      Drug Metabolism and Disposition May 2006, 34 (5) 836-847; DOI: https://doi.org/10.1124/dmd.105.008680

  7. Sohal, Bindi

    1. RAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708
      John R. Atack, Andy Pike, Ashley Clarke, Susan M. Cook, Bindi Sohal, Ruth M. McKernan and Gerard R. Dawson
      Drug Metabolism and Disposition May 2006, 34 (5) 887-893; DOI: https://doi.org/10.1124/dmd.105.006973

  8. Squires, E. James

    1. THE ROLE OF CYP2A AND CYP2E1 IN THE METABOLISM OF 3-METHYLINDOLE IN PRIMARY CULTURED PORCINE HEPATOCYTES
      Michael A. Terner, W. James Gilmore, Yanping Lou and E. James Squires
      Drug Metabolism and Disposition May 2006, 34 (5) 848-854; DOI: https://doi.org/10.1124/dmd.105.008128

  9. Stresser, David M.

    1. HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81
      J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James Wong
      Drug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569

  10. Sugiura, Mika

    1. EFFECT OF P-GLYCOPROTEIN ON INTESTINAL ABSORPTION AND BRAIN PENETRATION OF ANTIALLERGIC AGENT BEPOTASTINE BESILATE
      Rikiya Ohashi, Yukari Kamikozawa, Mika Sugiura, Hajime Fukuda, Hikaru Yabuuchi and Ikumi Tamai
      Drug Metabolism and Disposition May 2006, 34 (5) 793-799; DOI: https://doi.org/10.1124/dmd.105.007559

  11. Sugiyama, Yuichi

    1. INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID
      Harunobu Tahara, Hiroyuki Kusuhara, Kazuya Maeda, Hermann Koepsell, Eiichi Fuse and Yuichi Sugiyama
      Drug Metabolism and Disposition May 2006, 34 (5) 743-747; DOI: https://doi.org/10.1124/dmd.105.008375

T

  1. Tahara, Harunobu

    1. INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID
      Harunobu Tahara, Hiroyuki Kusuhara, Kazuya Maeda, Hermann Koepsell, Eiichi Fuse and Yuichi Sugiyama
      Drug Metabolism and Disposition May 2006, 34 (5) 743-747; DOI: https://doi.org/10.1124/dmd.105.008375

  2. Tamai, Ikumi

    1. EFFECT OF P-GLYCOPROTEIN ON INTESTINAL ABSORPTION AND BRAIN PENETRATION OF ANTIALLERGIC AGENT BEPOTASTINE BESILATE
      Rikiya Ohashi, Yukari Kamikozawa, Mika Sugiura, Hajime Fukuda, Hikaru Yabuuchi and Ikumi Tamai
      Drug Metabolism and Disposition May 2006, 34 (5) 793-799; DOI: https://doi.org/10.1124/dmd.105.007559

  3. Tenmizu, Daisuke

    1. THE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITOR
      Daisuke Tenmizu, Kiyoshi Noguchi, Hidetaka Kamimura, Hisakazu Ohtani and Yasufumi Sawada
      Drug Metabolism and Disposition May 2006, 34 (5) 800-806; DOI: https://doi.org/10.1124/dmd.105.008722

  4. Terner, Michael A.

    1. THE ROLE OF CYP2A AND CYP2E1 IN THE METABOLISM OF 3-METHYLINDOLE IN PRIMARY CULTURED PORCINE HEPATOCYTES
      Michael A. Terner, W. James Gilmore, Yanping Lou and E. James Squires
      Drug Metabolism and Disposition May 2006, 34 (5) 848-854; DOI: https://doi.org/10.1124/dmd.105.008128

  5. Thummel, Kenneth E.

    1. EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO
      Yang Dai, Mary F. Hebert, Nina Isoherranen, Connie L. Davis, Christopher Marsh, Danny D. Shen and Kenneth E. Thummel
      Drug Metabolism and Disposition May 2006, 34 (5) 836-847; DOI: https://doi.org/10.1124/dmd.105.008680

  6. Tokui, Taro

    1. OATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKER
      Rie Nakagomi-Hagihara, Daisuke Nakai, Kenji Kawai, Yasushi Yoshigae, Taro Tokui, Takaaki Abe and Toshihiko Ikeda
      Drug Metabolism and Disposition May 2006, 34 (5) 862-869; DOI: https://doi.org/10.1124/dmd.105.008888

  7. Trevaskis, Natalie L.

    1. AN EXAMINATION OF THE INTERPLAY BETWEEN ENTEROCYTE-BASED METABOLISM AND LYMPHATIC DRUG TRANSPORT IN THE RAT
      Natalie L. Trevaskis, Christopher J.H. Porter and William N. Charman
      Drug Metabolism and Disposition May 2006, 34 (5) 729-733; DOI: https://doi.org/10.1124/dmd.105.008102

  8. Tuman, R. W.

    1. N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES
      Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. Johnson
      Drug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274

U

  1. Ueng, Yune-Fang

    1. OXIDATIVE METABOLISM OF THE ALKALOID RUTAECARPINE BY HUMAN CYTOCHROME P450
      Yune-Fang Ueng, Ming-Jaw Don, Woan-Ching Jan, Shu-Yun Wang, Li-Kang Ho and Chieh-Fu Chen
      Drug Metabolism and Disposition May 2006, 34 (5) 821-827; DOI: https://doi.org/10.1124/dmd.105.007849

W

  1. Waldmeier, Felix

    1. PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO
      Markus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. Grassberger
      Drug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732

  2. Wall, Ulrika

    1. INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION
      Ulf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie Schützer
      Drug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607

  3. Wang, Lifei

    1. BIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITES
      Wenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith Humphreys
      Drug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856

  4. Wang, Shu-Yun

    1. OXIDATIVE METABOLISM OF THE ALKALOID RUTAECARPINE BY HUMAN CYTOCHROME P450
      Yune-Fang Ueng, Ming-Jaw Don, Woan-Ching Jan, Shu-Yun Wang, Li-Kang Ho and Chieh-Fu Chen
      Drug Metabolism and Disposition May 2006, 34 (5) 821-827; DOI: https://doi.org/10.1124/dmd.105.007849

  5. Wang, Yi

    1. ATP-DEPENDENT TRANSPORT OF ROSUVASTATIN IN MEMBRANE VESICLES EXPRESSING BREAST CANCER RESISTANCE PROTEIN
      Liyue Huang, Yi Wang and Scott Grimm
      Drug Metabolism and Disposition May 2006, 34 (5) 738-742; DOI: https://doi.org/10.1124/dmd.105.007534

  6. Waring, Jeffrey F.

    1. GENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATING
      Lysiane Richert, Michael J. Liguori, Catherine Abadie, Bruno Heyd, Georges Mantion, Nermin Halkic and Jeffrey F. Waring
      Drug Metabolism and Disposition May 2006, 34 (5) 870-879; DOI: https://doi.org/10.1124/dmd.105.007708

  7. Webster, Lindsey O.

    1. IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES
      Jarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. Polli
      Drug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615

  8. Wong, James

    1. HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81
      J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James Wong
      Drug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569

Y

  1. Yabuuchi, Hikaru

    1. EFFECT OF P-GLYCOPROTEIN ON INTESTINAL ABSORPTION AND BRAIN PENETRATION OF ANTIALLERGIC AGENT BEPOTASTINE BESILATE
      Rikiya Ohashi, Yukari Kamikozawa, Mika Sugiura, Hajime Fukuda, Hikaru Yabuuchi and Ikumi Tamai
      Drug Metabolism and Disposition May 2006, 34 (5) 793-799; DOI: https://doi.org/10.1124/dmd.105.007559

  2. Yamazoe, Yasushi

    1. DETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTS
      Rika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi Yamazoe
      Drug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623

  3. Yan, Z.

    1. N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES
      Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. Johnson
      Drug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274

  4. Yoshigae, Yasushi

    1. OATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKER
      Rie Nakagomi-Hagihara, Daisuke Nakai, Kenji Kawai, Yasushi Yoshigae, Taro Tokui, Takaaki Abe and Toshihiko Ikeda
      Drug Metabolism and Disposition May 2006, 34 (5) 862-869; DOI: https://doi.org/10.1124/dmd.105.008888

Z

  1. Zeldin, Darryl C.

    1. THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
      Mary F. Paine, Heather L. Hart, Shana S. Ludington, Robert L. Haining, Allan E. Rettie and Darryl C. Zeldin
      Drug Metabolism and Disposition May 2006, 34 (5) 880-886; DOI: https://doi.org/10.1124/dmd.105.008672

  2. Zenke, Gerhard

    1. PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO
      Markus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. Grassberger
      Drug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732

  3. Zhang, Donglu

    1. BIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITES
      Wenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith Humphreys
      Drug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856

  4. Zhang, Duxi

    1. BIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITES
      Wenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith Humphreys
      Drug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856

  5. Zhang, Hao

    1. BIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITES
      Wenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith Humphreys
      Drug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856

  6. Zhang, J. George

    1. HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81
      J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James Wong
      Drug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569

  7. Zimmerlin, Alfred G.

    1. PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO
      Markus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. Grassberger
      Drug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732

  8. Zollinger, Markus

    1. PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO
      Markus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. Grassberger
      Drug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732
Back to top

In this issue